undamentalytics Newsletter
Sign in

Bioventus Inc. income statement

In fiscal 2025, Bioventus Inc. reported revenue of $568m, down 0.9% on the year before, operating income of $54.0m (a 9.5% margin) and net income of $22.7m, or $0.33 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue340321431512512573568586
Cost of revenue9188128181184185180183
Gross profit249234303331328388388402
Research and development1111192413141212
Selling, general and administrative198193254332304344314327
Operating income312112−167−82−155457
Income before tax10169−189−121−522640
Income tax21−2−440−5−2−24
Net income71619−159−156−362357
Diluted EPS——−$0.15−$2.59−$2.49−$0.56$0.33$0.80
Diluted shares (average)——45m61m63m65m69m71m
EBITDA625047−112−243410182

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ATRC vs BVSBVS vs TMDXBVS vs GKOSAORT vs BVS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bioventus Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioventus Inc.